IMPACT Announces Completion of RMB 250 million Sr. D++ Financing

IMPACT Announces Data Presentation of ATRi IMP9064 at ESMO2024

The Phase 3 clinical trial data of Senaparib has been published in prestigious international journal Nature Medicine, positioning it as a promising first-line maintenance treatment option for the all-comer population in advanced ovarian cancer

IMPACT Presented the Clinical Data of FLAMES at ESGO Congress

IMPACT Announces FPD in U.S. of PARP1 selective inhibitor

IMPACT Entered into Commercial Partnership with Huadong Medicine

IMPACT Therapeutics Presented the Clinical Data for Senaparib as First-line Maintenance Therapy in Advanced Ovarian Cancer Patients at IGCS Annual Global Meeting 2023 as a Plenary oral Presentation

IMPACT Therapeutics presented preliminary clinical data of WEE1 inhibitor IMP7068 at ESMO Congress 2023

IMPACT Announces Presentation of the Preliminary Clinical Data for Senaparib in BRCA1/2 Mutated Recurrent Platinum Sensitive Ovarian Cancer and ATR Inhibitor IMP9064 Monotherapy Dose Escalation of FIH Study at the ESMO 2023

IMPACT Therapeutics Presented Pivotal Phase 3 Clinical Data for Senaparib as First-line Maintenance Therapy in Advanced Ovarian Cancer Patients at ESMO Congress 2023 as a Proffered Late-Breaking Paper Presentation

IMPACT Therapeutics to present Ph3 pivotal clinical trial data of Senaparib (IMP4297) as Maintenance Treatment in Patients with Advanced Ovarian Cancer at the 2023 ESMO Congress as Late-Breaking Abstract

IMPACT Therapeutics Announces IND Clearance from U.S. FDA Enabling Phase 1 Initiation for Highly Selective PARP1 Inhibitor, IMP1734

IMPACT Therapeutics Announces Senaparib NDA Acceptance by the NMPA for first-line Maintenance Treatment of Patients with Advanced Ovarian Cancer

Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors

IMPACT Therapeutics Presents Data of WEE1 Inhibitor IMP7068 at the 2023 American Association for Cancer Research (AACR) Annual Meeting

IMPACT Therapeutics Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint

IMPACT Therapeutics Presents the Clinical Data from phase I study of Wee1 Inhibitor IMP7068 at ESMO Congress 2022

FDA Granted Orphan Drug Designation to IMP4297+TMZ for SCLC

IMPACT Announces Presentation of the Clinical Data for the dose escalation and dose expansion of Senaparib in Combination with Temozolomide at the ASCO2022

Announcement: Dr. Timothy Yap Joined Scientific Advisory Board of Impact Therapeutics

IMPACT Announces Presentation of the Clinical Data for Senaparib in Combination with Temozolomide and the Monotherapy of Wee1 Inhibitor at the ASCO 2022

IMPACT Announces Acceptance of Two Abstracts of Senaparib for Presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Impact Therapeutics Announces Completion of Series D1 Financing

IMPACT Therapeutics Announces that PARP inhibitor Senaparib in combination with temozolomide receives IND Approval from the NMPA

IMPACT Therapeutics ' PARP Inhibitor Senaparib Targeting Prostate Cancer Approved for Clinical Trials in China

IMPACT Therapeutics Announced ATR Inhibitor IMP9064 IND Clearance by FDA

IMPACT Therapeutics Appoints Dr. Chun-Pyn Shen as Head of Regulatory Affairs

IMPACT Therapeutics and Genetron Health Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline

IMPACT Therapeutics and Cyclica Team Up to Advance Differentiated Anti-cancer Drug Development

IMPACT Therapeutics' Hedgehog Inhibitor Approved for Clinical Trials in China

IMPACT Therapeutics and Burning Rock Announce a Partnership for Companion Diagnostics Development

Impact Therapeutics Announced IND Approval of Senaparib targeting Prostate Cancer in the U.S.

IMPACT Therapeutics Announced First-Patient-Dose of Wee1 Inhibitor IMP7068 in the U.S.

IMPACT Therapeutics Announced the IND Approval for its Wee1 Inhibitor IMP7068 from the NMPA

IMPACT Therapeutics Announces $50 Million Series C+ Financing

IMPACT announced PARP inhibitor Senaparib in combination with temozolomide IND clearance by US FDA

IMPACT announced Wee1 inhibitor IMP7068 IND clearance by US FDA

IMPACT Therapeutics and Junshi Biosciences Establish Joint Venture to Develop PARP Inhibitor Senapar

Announcement: Dr. Alan D’Andrea Joined Scientific Advisory Board of IMPACT Therapeutics

IMPACT Announced Dosing of the First Patient in Senaparib and Temozolomide Combination Study

IMPACT Announced First-Patient-In of its PARP inhibitor IMP4297 in Phase 3 Study

 

Announcement: Dr. Chih-Yi Hsieh was appointed as Chief Medical Officer of IMPACT Therapeutics

 

公司资料标题占位

公司资料标题占位 公司资料标题占位 公司资料标题占位题占位 公司资

提名委员会职权范围

2020年中期报告

IMPACT Announced First-Patient-In of its PARP inhibitor IMP4297 Pivotal Study

2025

 

位 公司资料标题占位标题占位 公司资料标题占位

公司资料标题占位 公司资料标题占位 公司资料标题占位题占位 公司资料标题占位公司资料标

薪酬委员会职权范围

2020年中期报告

2024

 

资料标题占位 公司资料标题占位标题占位 公司资料标题占位

公司资料标题占位 公司资料标题占位 公司资料标题占

审核委员会职权范围

2020年中期报告

Dr. Cong Xu

2023

 

公司资料标题占位 公司资料标题占位 公司资料标题占位标题占位 公司资料标题占位

公司资料标题占位 公司资料标题占位 公司资料标题占位

参选流程

2020年中期报告

IMPACT Therapeutics Raises $30 Million In Series C Financing

2022

Ning Ma

 

公司资料标题占位 公司资料标题占位 公司资料标题占位标题占位 公司资料标题占位占位

公司资料标题占位 公司资料标题占位 公司资料标题占位

2020年中期报告

2021

IMPACT Received IMP4297 Chinese IND Approval

Dr. Timothy Yap

 

Dr. Yanhua Xu

Self Study

员工活动

内容4

公司资料标题占

公司资料标题占位 公司资料标题占位 公司资料标题占位题占位 公司资料标题占位

Dr. Alan D. D'Andrea

2020年中期报告

Dr. Alan D. D'Andrea

Strategy

2020

 

General & Leadership Training

节日福利

公司资料标题占位 公司资料标题占位 公司资料标题占位标题占位 公司资

公司资料标题占位 公司资料标题占位 公司资料标题占位题占位 公司资料标题占位

Dr. Andrew Zhu

2020年中期报告

Dr. Ye Tian

Value

2019

IMPACT Therapeutics is pleased to announce the closing of a round of VC financing.

Cell Lung Cancer (combo with Temozolomide)*ODD

Functional Training

员工奖励

内容2

Nanjing Yingpai Pharmaceutical Co., Ltd

公司资料标题占位 公司资料标题占位 公

公司资料标题占位 公司资料标题占位 公司资料标题占位

Dr. Robert Weinberg

2020年中期报告

Dr. Robert Weinberg

Dr. Sui Xiong Cai

Vision

2018

IMPACT Therapeutics successfully completed A round of financing

Ovarian Cancer (SABRINA Study, 3L+,BRCAm)*Pivotal study

促进和鼓励人才发展

New Employee Orientation

医疗保险

内容1

Shanghai Yingpai Pharmaceutical Co., Ltd

公司资料标题占位 公司资料标题占位 公司资料标题占位标题占位 公司资料标题占位

司资料标题占位 公司资料标题占位 公司资料标题占位

推介材料

Dr. Douglas Hanahan

2020年中期报告

Our Science

Partnership

About Us

Dr. Douglas Hanahan

Mission

2017

IMS reported IMPACT Therapeutics in its R&D FOCUS drug news

Website Privacy Notice

The Legal Statement on the Website of IMPACT Therapeutics 

Clinical Trial Privacy Notice

派舒宁

Ovarian Cancer (FLAMES Study, 1L maintenance)

2015

2014

2009